Technical Analysis for BGNE - BeiGene, Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical BGNE trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | -1.03% | |
| MACD Bearish Signal Line Cross | Bearish | -1.03% | |
| Inside Day | Range Contraction | -1.03% | |
| 20 DMA Resistance | Bearish | 1.76% | |
| Inside Day | Range Contraction | 1.76% | |
| Down 3 Days in a Row | Weakness | 1.76% | |
| Down 4 Days in a Row | Weakness | 1.76% | |
| Fell Below 20 DMA | Bearish | 0.17% | |
| Fell Below 50 DMA | Bearish | 0.17% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | 0.17% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 1% | about 1 hour ago |
| 20 DMA Resistance | about 2 hours ago |
| 20 DMA Support | about 3 hours ago |
| 60 Minute Opening Range Breakdown | about 3 hours ago |
| Up 3% | about 5 hours ago |
Get a Trading Assistant
- Earnings date: 09/27/2019
BeiGene, Ltd. Description
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancers Monoclonal Antibody Monoclonal Antibodies Lymphoma Oncogenes Protein Kinase Kras Humanized Antibody Ras Subfamily Bruton's Tyrosine Kinase Rp1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 388.97 |
| 52 Week Low | 155.16 |
| Average Volume | 256,593 |
| 200-Day Moving Average | 288.81 |
| 50-Day Moving Average | 320.08 |
| 20-Day Moving Average | 315.54 |
| 10-Day Moving Average | 328.41 |
| Average True Range | 15.15 |
| ADX | 17.45 |
| +DI | 21.05 |
| -DI | 27.65 |
| Chandelier Exit (Long, 3 ATRs ) | 314.40 |
| Chandelier Exit (Short, 3 ATRs ) | 334.75 |
| Upper Bollinger Band | 351.50 |
| Lower Bollinger Band | 279.58 |
| Percent B (%b) | 0.48 |
| BandWidth | 22.79 |
| MACD Line | 0.37 |
| MACD Signal Line | 0.73 |
| MACD Histogram | -0.3594 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 330.84 | ||||
| Resistance 3 (R3) | 329.99 | 323.53 | 328.04 | ||
| Resistance 2 (R2) | 323.53 | 319.24 | 323.95 | 327.10 | |
| Resistance 1 (R1) | 318.76 | 316.59 | 321.14 | 319.61 | 326.16 |
| Pivot Point | 312.30 | 312.30 | 313.49 | 312.72 | 312.30 |
| Support 1 (S1) | 307.53 | 308.01 | 309.92 | 308.39 | 301.84 |
| Support 2 (S2) | 301.07 | 305.36 | 301.49 | 300.90 | |
| Support 3 (S3) | 296.30 | 301.07 | 299.96 | ||
| Support 4 (S4) | 297.16 |
